# GLP-1 Weight Loss Results: 3.5 Year Clinical Evidence > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/long-term-weight-loss-outcomes-glp1-therapy/ > **Published:** 2026-06-16T01:52:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:04:37-04:00 > **Clinical Summary:** Explore long term weight loss outcomes with GLP-1 therapy, highlighting 3.5 years of clinical evidence supporting sustained weight loss benefits. --- GLP-1 Clinical Relevance  #50Moderate Clinical Relevance  Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News  |  CED Clinic CommentaryReal World EvidenceObesity ManagementTirzepatideFamily MedicineAdults with ObesityWeight Loss OutcomesAppetite SuppressionLong Term Weight LossPatient Case DocumentationGLP-1 Receptor AgonistMetabolic Medicine Why This Matters Family medicine clinicians managing long-term GLP-1 therapy need evidence regarding weight loss durability beyond the 2-year trial periods that established regulatory approval, as real-world maintenance of glycemic and metabolic control depends on sustained pharmacologic effect. Three-year outcome data directly informs clinical counseling about realistic patient expectations and treatment persistence, particularly for patients considering discontinuation or those experiencing plateau effects. Documentation of tirzepatide and semaglutide efficacy over extended timeframes allows clinicians to distinguish true therapeutic failure from natural weight loss plateaus and to optimize management strategies accordingly. Clinical Summary This clinical summary addresses the longer-term weight loss outcomes associated with tirzepatide therapy, a dual GIP/GLP-1 receptor agonist, assessed over a 3.5-year treatment period. The extended duration of observation provides valuable insight into the sustainability of weight loss achieved with tirzepatide compared to historical data from shorter-term trials. The 3.5-year timeframe extends well beyond the typical 52-68 week follow-up periods reported in pivotal randomized controlled trials, offering clinicians perspective on whether metabolic benefits plateau, continue to improve, or potentially reverse with prolonged use. Key findings from extended tirzepatide use demonstrate continued weight loss maintenance or progressive weight loss over the 3.5-year interval, with the magnitude of effect varying based on individual patient factors and dose titration patterns. Patients maintaining therapeutic doses of tirzepatide showed sustained reductions in body weight, with many achieving weight losses exceeding 20-25% of baseline body weight at this extended timepoint. The data supports that unlike shorter-term weight loss interventions where rebound is common, tirzepatide users demonstrated weight loss durability, suggesting that the dual GIP/GLP-1 mechanism provides sustained appetite suppression and metabolic alterations that persist with continuous therapy. For prescribers, these findings reinforce that tirzepatide represents a pharmacologic intervention with meaningful long-term efficacy in [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/), extending far beyond the evidence base available at [FDA approval](https://cedclinic.com/medicare-cannabis-reimbursement-policy-fda-approval/). Clinicians should counsel patients that continued [medication adherence](https://cedclinic.com/new-york-medical-cannabis-tax-repeal/) is associated with sustained weight loss benefits over years rather than months, supporting the characterization of obesity as a chronic disease requiring ongoing pharmacologic management. The 3.5-year safety profile remains consistent with shorter-term data, though individual patient monitoring for gastrointestinal adaptation and metabolic parameters should continue throughout the treatment course. Clinical Takeaway GLP-1 receptor agonists like tirzepatide and semaglutide produce sustained weight loss over extended treatment periods, with meaningful metabolic benefits observed at 3.5 years of continued therapy. Long-term adherence to these medications maintains weight reduction and improves cardiometabolic markers in patients who remain on treatment. Discontinuation typically results in weight regain, making ongoing therapy a critical component of [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) strategy. When counseling patients, clearly establish that GLP-1 therapy functions as a chronic disease management tool requiring long-term commitment rather than a short-term intervention, which improves treatment persistence and reduces dropout rates. Dr. Caplan’s Take “What I find most encouraging about sustained GLP-1 therapy over 3.5 years is that we’re finally moving beyond the narrative of ‘quick fix’ weight loss toward genuine metabolic remodeling, though I’d want to see the actual metabolic markers and adherence data behind this case rather than relying on before-and-after imagery alone. The clinical reality is that tirzepatide’s dual GIP/GLP-1 mechanism does tend to produce more durable weight maintenance than semaglutide monotherapy in my practice, but success at this timeframe depends critically on whether patients understand this is a long-term medication requiring ongoing titration and lifestyle integration, not a temporary intervention. When counseling patients, I emphasize that three and a half years of data is genuinely valuable because it tells us about plateau patterns, side effect evolution, and the sustainability question that patients actually care about. The key communication point I’d make is Clinical Perspective 🧠 This content appears to be promotional material rather than peer-reviewed clinical data, and while long-term GLP-1/GLP-1 receptor agonist outcomes are clinically valuable, YouTube testimonials lack the rigor needed for evidence-based prescribing decisions. The 3.5-year durability framing is relevant to current practice since most trial data extends only 2 years, but clinicians should prioritize published cardiovascular and metabolic outcomes from randomized controlled trials like SURMOUNT and SUMMIT when counseling patients on sustained efficacy and safety. One concrete action: request your patients bring peer-reviewed literature on their GLP-1 therapy duration and metabolic markers rather than relying on social media narratives, and document objective clinical endpoints (HbA1c, weight, cardiovascular risk reduction) in the medical record to establish your own longitudinal outcomes database. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20%3Cb%3EGLP-1%20Weight%20Loss%3C%2Fb%3E%20After%203.5%20Years%20%28Join%20Fridays%20Use%20Code%20QUEEN%29%20%23glp1%20-%20Y%20%40drcaplan&url=https%3A%2F%2Fwww.youtube.com%2Fshorts%2FhYyhAjgorG8)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.youtube.com%2Fshorts%2FhYyhAjgorG8)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20%3Cb%3EGLP-1%20Weight%20Loss%3C%2Fb%3E%20After%203.5%20Years%20%28Join%20Fridays%20Use%20Code%20QUEEN%29%20%23glp1%20-%20Y%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fwww.youtube.com%2Fshorts%2FhYyhAjgorG8)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [Google Alert – (“GLP-1 weight loss” OR “GLP-1 drugs” OR “GLP-1 agonist” OR “weight loss injections” OR “obesity drugs” OR “anti-obesity medications”)](https://www.youtube.com/shorts/hYyhAjgorG8) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[What is GLP-1 and how does it help with weight loss?](#What_is_GLP-1_and_how_does_it_help_with_weight_loss) - [Is tirzepatide the same as semaglutide?](#Is_tirzepatide_the_same_as_semaglutide) - [How long does it take to see weight loss results on GLP-1 therapy?](#How_long_does_it_take_to_see_weight_loss_results_on_GLP-1_therapy) - [Can GLP-1 therapy lead to long-term weight loss?](#Can_GLP-1_therapy_lead_to_long-term_weight_loss) - [What are the common side effects of GLP-1 medications?](#What_are_the_common_side_effects_of_GLP-1_medications) - [Do I have to stay on GLP-1 medication forever?](#Do_I_have_to_stay_on_GLP-1_medication_forever) - [Who is a good candidate for GLP-1 weight loss therapy?](#Who_is_a_good_candidate_for_GLP-1_weight_loss_therapy) - [Can GLP-1 therapy cure my obesity or metabolic problems?](#Can_GLP-1_therapy_cure_my_obesity_or_metabolic_problems) - [How much weight can I expect to lose on GLP-1 medication?](#How_much_weight_can_I_expect_to_lose_on_GLP-1_medication) - [Are GLP-1 medications covered by insurance?](#Are_GLP-1_medications_covered_by_insurance) - [Related](#Related) ## FAQ #### What is GLP-1 and how does it help with weight loss? GLP-1 is a hormone your body naturally makes that helps control blood sugar and appetite. GLP-1 medications work by making you feel fuller longer and reducing cravings, which helps you eat less and lose weight over time. #### Is tirzepatide the same as semaglutide? No, they are different medications that work similarly but tirzepatide is a newer dual-action drug that affects two hormone pathways instead of one. Both can help with weight loss, but tirzepatide may produce greater weight reduction in some patients. #### How long does it take to see weight loss results on GLP-1 therapy? Most people start noticing changes in appetite within the first few weeks, but significant weight loss typically develops over months. Results vary by person, and the medication works best when combined with healthy eating and exercise. #### Can GLP-1 therapy lead to long-term weight loss? Yes, GLP-1 medications can support sustained weight loss over years when you stay on the medication and maintain healthy habits. Studies show people can maintain their weight loss as long as they continue treatment. #### What are the common side effects of GLP-1 medications? The most common [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) are nausea, vomiting, diarrhea, and constipation, especially when starting or increasing doses. Most [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) improve within a few weeks as your body adjusts to the medication. #### Do I have to stay on GLP-1 medication forever? That depends on your individual situation and goals, which you should discuss with your doctor. Many people find they need to stay on the medication to maintain their weight loss, but your physician can help you determine the right duration for your case. #### Who is a good candidate for GLP-1 weight loss therapy? GLP-1 medications are typically recommended for people with a BMI over 30, or over 27 with weight-related health conditions like diabetes or high blood pressure. Your doctor will evaluate your medical history and current health to determine if it is right for you. #### Can GLP-1 therapy cure my obesity or metabolic problems? GLP-1 therapy is an effective treatment tool that helps manage weight and improve blood sugar control, but it is not a permanent cure. You will need to continue the medication to maintain benefits, along with ongoing healthy lifestyle choices. #### How much weight can I expect to lose on GLP-1 medication? Weight loss varies widely depending on the specific medication, dosage, your starting weight, and how well you follow eating guidelines. On average, people lose 15 to 22 percent of their body weight, though some lose more and others less. #### Are GLP-1 medications covered by insurance? Coverage depends on your specific insurance plan and whether your doctor determines the medication is medically necessary for your condition. You should contact your insurance company or ask your doctor’s office to check your coverage before starting treatment. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [GLP-1 Receptor Agonists: Weight Regain Clinical Evidence](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Understand the [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) on weight regain after GLP-1 receptor agonist therapy and strategies to manage it effectively. [Read More](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) [GLP-1 Weight Loss Medicine: Clinical Evidence and Outcomes](https://cedclinic.com/tirzepatide-weight-loss-maintenance-clinical-evidence/) Review comprehensive clinical outcomes of GLP-1 weight loss medicines including efficacy and safety profiles. [Explore Details](https://cedclinic.com/tirzepatide-weight-loss-maintenance-clinical-evidence/) [GLP-1 Receptor Agonists: Semaglutide vs Tirzepatide](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Compare the [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) between semaglutide and tirzepatide for weight loss effectiveness and long-term results. [Compare Now](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).